Semin Liver Dis 2010; 30(1): 003-016
DOI: 10.1055/s-0030-1247128
© Thieme Medical Publishers

Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis

Morris Sherman1
  • 1Department of Medicine, University of Toronto and University Health Network, Toronto, Canada
Further Information

Publication History

Publication Date:
19 February 2010 (online)


Hepatocellular carcinoma (HCC) is increasing in incidence in many countries, and is the most common cause of death in patients with cirrhosis. With regular surveillance, small early HCC lesions can be identified. An algorithm has been developed that allows for diagnosis of these lesions. Very early HCC lesions have high cure rates with appropriate treatment. If all these factors are in place most HCCs can be cured.


  • 1 Bosch F X, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127(5, Suppl 1) S5-S16
  • 2 Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan.  Cancer Res. 1987;  47(18) 4967-4972
  • 3 Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94.  Lancet. 1997;  350(9085) 1142-1143
  • 4 Deuffic S, Poynard T, Buffat L, Valleron A J. Trends in primary liver cancer.  Lancet. 1998;  351(9097) 214-215
  • 5 Stroffolini T, Andreone P, Andriulli A et al.. Characteristics of hepatocellular carcinoma in Italy.  J Hepatol. 1998;  29(6) 944-952
  • 6 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  340(10) 745-750
  • 7 Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan.  J Gastroenterol. 2009;  44(Suppl 19) 102-107
  • 8 Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.  Hepatology. 2008;  48(1) 137-145
  • 9 King H, Locke F B. Cancer mortality among Chinese in the United States.  J Natl Cancer Inst. 1980;  65(5) 1141-1148
  • 10 Rosenblatt K A, Weiss N S, Schwartz S M. Liver cancer in Asian migrants to the United States and their descendants.  Cancer Causes Control. 1996;  7(3) 345-350
  • 11 McCredie M, Williams S, Coates M. Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975-1995.  Br J Cancer. 1999;  79(7-8) 1277-1282
  • 12 Beasley R P, Hwang L Y, Lin C C, Chien C S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.  Lancet. 1981;  2(8256) 1129-1133
  • 13 Sakuma K, Saitoh N, Kasai M et al.. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study.  Hepatology. 1988;  8(6) 1642-1646
  • 14 Fattovich G, Giustina G, Degos F et al.. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.  Gastroenterology. 1997;  112(2) 463-472
  • 15 Bruix J, Barrera J M, Calvet X et al.. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.  Lancet. 1989;  2(8670) 1004-1006
  • 16 Niederau C, Lange S, Heintges T et al.. Prognosis of chronic hepatitis C: results of a large, prospective cohort study.  Hepatology. 1998;  28(6) 1687-1695
  • 17 Sun C A, Wu D M, Lin C C et al.. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan.  Am J Epidemiol. 2003;  157(8) 674-682
  • 18 Ikeda K, Saitoh S, Koida I et al.. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.  Hepatology. 1993;  18(1) 47-53
  • 19 Benvegnù L, Fattovich G, Noventa F et al.. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study.  Cancer. 1994;  74(9) 2442-2448
  • 20 Cottone M, Turri M, Caltagirone M et al.. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein.  J Hepatol. 1994;  21(6) 1029-1034
  • 21 Borzio M, Bruno S, Roncalli M et al.. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study.  Gastroenterology. 1995;  108(3) 812-817
  • 22 Pateron D, Ganne N, Trinchet J C et al.. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.  J Hepatol. 1994;  20(1) 65-71
  • 23 Colombo M, de Franchis R, Del Ninno E et al.. Hepatocellular carcinoma in Italian patients with cirrhosis.  N Engl J Med. 1991;  325(10) 675-680
  • 24 Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004.  Hepatology. 2008;  48(1) 137-145
  • 25 Fargion S, Fracanzani A L, Piperno A et al.. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis.  Hepatology. 1994;  20(6) 1426-1431
  • 26 Caballería L, Parés A, Castells A, Ginés A, Bru C, Rodés J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis.  Am J Gastroenterol. 2001;  96(4) 1160-1163
  • 27 Goedert J J. Second Multicenter Hemophilia Cohort Study . Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001–2003.  Haemophilia. 2005;  11(5) 516-528
  • 28 Livraghi T, Meloni F, Di Stasi M et al.. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?.  Hepatology. 2008;  47(1) 82-89
  • 29 Sala M, Llovet J M, Vilana R Barcelona Clínic Liver Cancer Group et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma.  Hepatology. 2004;  40(6) 1352-1360
  • 30 Lu S N, Wang J H, Chen P F et al.. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults.  Cancer Epidemiol Biomarkers Prev. 2008;  17(7) 1813-1821
  • 31 Mima S, Sekiya C, Kanagawa H et al.. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan.  J Gastroenterol Hepatol. 1994;  9(4) 361-365
  • 32 Yu E W, Chie W C, Chen T H. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?.  Cancer J. 2004;  10(5) 317-325
  • 33 Chan A C, Poon R T, Ng K K, Lo C M, Fan S T, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening.  Ann Surg. 2008;  247(4) 666-673
  • 34 Stravitz R T, Heuman D M, Chand N et al.. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.  Am J Med. 2008;  121(2) 119-126
  • 35 Chen J G, Parkin D M, Chen Q G et al.. Screening for liver cancer: results of a randomised controlled trial in Qidong, China.  J Med Screen. 2003;  10(4) 204-209
  • 36 Zhang B H, Yang B H, Tang Z Y. Randomized controlled trial of screening for hepatocellular carcinoma.  J Cancer Res Clin Oncol. 2004;  130(7) 417-422
  • 37 Sarasin F P, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis.  Am J Med. 1996;  101(4) 422-434
  • 38 Arguedas M R, Chen V K, Eloubeidi M A, Fallon M B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.  Am J Gastroenterol. 2003;  98(3) 679-690
  • 39 Patel D, Terrault N A, Yao F Y, Bass N M, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.  Clin Gastroenterol Hepatol. 2005;  3(1) 75-84
  • 40 Lin O S, Keeffe E B, Sanders G D, Owens D K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.  Aliment Pharmacol Ther. 2004;  19(11) 1159-1172
  • 41 Thompson Coon J, Rogers G, Hewson P et al.. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.  Br J Cancer. 2008;  98(7) 1166-1175
  • 42 Ishizawa T, Hasegawa K, Aoki T et al.. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.  Gastroenterology. 2008;  134(7) 1908-1916
  • 43 Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases . Management of hepatocellular carcinoma.  Hepatology. 2005;  42(5) 1208-1236
  • 44 Chen C J, Yang H I, Su J REVEAL-HBV Study Group et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  JAMA. 2006;  295(1) 65-73
  • 45 Tong M J, Hsien C, Song J J et al.. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis.  Dig Dis Sci. 2009;  54(6) 1337-1346
  • 46 Chen T H, Chen C J, Yen M F et al.. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.  Int J Cancer. 2002;  98(2) 257-261
  • 47 Chen G, Lin W, Shen F, Iloeje U H, London W T, Evans A A. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.  Am J Gastroenterol. 2006;  101(8) 1797-1803
  • 48 Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years.  Gut. 2008;  57(1) 84-90
  • 49 Sánchez-Tapias J M, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients.  Gastroenterology. 2002;  123(6) 1848-1856
  • 50 Yang H I, Yeh S H, Chen P J REVEAL-HBV Study Group et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.  J Natl Cancer Inst. 2008;  100(16) 1134-1143
  • 51 Yuen M F, Tanaka Y, Fong D Y et al.. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.  J Hepatol. 2009;  50(1) 80-88
  • 52 Chen C J, Yang H I, Iloeje U H et al.. A risk function nomogram for predicting HCC in patients with chronic hepatitis B: The REVEAL.-HBV Study.  J Hepatol. 2007;  46(Suppl 1) S180
  • 53 Lok A S, Seeff L B, Morgan T R HALT-C Trial Group et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.  Gastroenterology. 2009;  136(1) 138-148
  • 54 Trevisani F, D'Intino P E, Morselli-Labate A M et al.. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.  J Hepatol. 2001;  34(4) 570-575
  • 55 Pateron D, Ganne N, Trinchet J C et al.. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.  , [see comments] J Hepatol. 1994;  20(1) 65-71
  • 56 Marrero J A, Su G L, Wei W et al.. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.  Hepatology. 2003;  37(5) 1114-1121
  • 57 Durazo F A, Blatt L M, Corey W G et al.. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.  J Gastroenterol Hepatol. 2008;  23(10) 1541-1548
  • 58 Sterling R K, Jeffers L, Gordon F et al.. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.  Clin Gastroenterol Hepatol. 2009;  7(1) 104-113
  • 59 Di Bisceglie A M, Hoofnagle J H. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B.  Cancer. 1989;  64(10) 2117-2120
  • 60 Di Bisceglie A M, Sterling R K, Chung R T HALT-C Trial Group et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.  J Hepatol. 2005;  43(3) 434-441
  • 61 Sherman M. Alphafetoprotein: an obituary.  J Hepatol. 2001;  34(4) 603-605
  • 62 Zhou X D, Tang Z Y, Fan J et al.. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma.  J Cancer Res Clin Oncol. 2009;  135(8) 1073-1080
  • 63 Welzel T M, Graubard B I, El-Serag H B et al.. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.  Clin Gastroenterol Hepatol. 2007;  5(10) 1221-1228
  • 64 Fujiyama S, Izuno K, Yamasaki K, Sato T, Taketa K. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.  Tumour Biol. 1992;  13(5-6) 316-323
  • 65 Okuda H, Nakanishi T, Takatsu K et al.. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.  Cancer. 1999;  85(4) 812-818
  • 66 Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.  J Gastroenterol. 2007;  42(12) 962-968
  • 67 Carr B I, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States.  Dig Dis Sci. 2007;  52(3) 776-782
  • 68 Leerapun A, Suravarapu S V, Bida J P et al.. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.  Clin Gastroenterol Hepatol. 2007;  5(3) 394-402, quiz 267
  • 69 Sterling R K, Jeffers L, Gordon F et al.. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.  Am J Gastroenterol. 2007;  102(10) 2196-2205
  • 70 Capurro M, Wanless I R, Sherman M et al.. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.  Gastroenterology. 2003;  125(1) 89-97
  • 71 Yamauchi N, Watanabe A, Hishinuma M et al.. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.  Mod Pathol. 2005;  18(12) 1591-1598
  • 72 Marrero J A, Romano P R, Nikolaeva O et al.. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.  J Hepatol. 2005;  43(6) 1007-1012
  • 73 Bolondi L, Sofia S, Siringo S et al.. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.  Gut. 2001;  48(2) 251-259
  • 74 Chen T H, Chen C J, Yen M F et al.. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.  Int J Cancer. 2002;  98(2) 257-261
  • 75 Larcos G, Sorokopud H, Berry G, Farrell G C. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation.  AJR Am J Roentgenol. 1998;  171(2) 433-435
  • 76 Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer.  J Med Screen. 1999;  6(2) 108-110
  • 77 Kobayashi K, Sugimoto T, Makino H et al.. Screening methods for early detection of hepatocellular carcinoma.  Hepatology. 1985;  5(6) 1100-1105
  • 78 Takayasu K, Moriyama N, Muramatsu Y et al.. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients.  AJR Am J Roentgenol. 1990;  155(1) 49-54
  • 79 Miller W J, Baron R L, Dodd III G D, Federle M P. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients.  Radiology. 1994;  193(3) 645-650
  • 80 Santagostino E, Colombo M, Rivi M Study Group of the Association of Italian Hemophilia Centers et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus.  Blood. 2003;  102(1) 78-82
  • 81 Trevisani F, Cantarini M C, Labate A M Italian Liver Cancer (ITALICA) group et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival.  Am J Gastroenterol. 2004;  99(8) 1470-1476
  • 82 Kim D Y, Han K H, Ahn S H et al.. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience).  Hepatology. 2007;  46(Suppl 1) 403A
  • 83 Nicolau C, Vilana R, Catalá V et al.. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions.  AJR Am J Roentgenol. 2006;  186(1) 158-167
  • 84 Iannaccone R, Laghi A, Catalano C et al.. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis.  Radiology. 2005;  234(2) 460-467
  • 85 Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view.  Liver Transpl. 2004;  10(2, Suppl 1) S3-S8
  • 86 Nakashima T, Kojiro M. Hepatocellular Carcinoma. Tokyo; Springer-Verlag 1987
  • 87 International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia . Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia.  Hepatology. 2009;  49(2) 658-664
  • 88 Libbrecht L, Severi T, Cassiman D et al.. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.  Am J Surg Pathol. 2006;  30(11) 1405-1411
  • 89 Coston W M, Loera S, Lau S K et al.. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.  Am J Surg Pathol. 2008;  32(3) 433-444
  • 90 Park Y N, Kojiro M, Di Tommaso L et al.. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules.  Cancer. 2007;  109(5) 915-923
  • 91 Iwasaki M, Furuse J, Yoshino M, Ryu M, Moriyama N, Mukai K. Sonographic appearances of small hepatic nodules without tumor stain on contrast-enhanced computed tomography and angiography.  J Clin Ultrasound. 1998;  26(6) 303-307
  • 92 Rimola J, Forner A, Reig M et al.. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.  Hepatology. 2009;  50(3) 791-798
  • 93 Forner A, Vilana R, Ayuso C et al.. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.  Hepatology. 2008;  47(1) 97-104
  • 94 Khalili K, Kim T Y, Jang H J, Haider M A, Guindi M, Sherman M. Implementation of AASLD hepatocellular carcinoma practice guidelines in north america:two years of experience.  Hepatology. 2008;  48(Suppl 1) 362A

Morris ShermanM.B. B.Ch. Ph.D. F.R.C.P.(C.) 

Toronto General Hospital, Room #NCSB 11C 1252

585 University Avenue, Toronto, Ontario, Canada M5G 2N2